Esperion Therapeutics ESPR Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's accrued expenses?
- Esperion Therapeutics (ESPR) reported accrued expenses of $6.94M in Q1 2026.
- How has Esperion Therapeutics's accrued expenses changed year-over-year?
- Esperion Therapeutics's accrued expenses increased by 8.1% year-over-year, from $6.42M to $6.94M.
- What is the long-term trend for Esperion Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Esperion Therapeutics's accrued expenses has grown at a 196.6% compound annual growth rate (CAGR), from $52K to $11.94M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.